Extended indication Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL).
Therapeutic value Possible added value
Total cost 340,000.00
Registration phase Clinical trials

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information